All In Biotech

Drug Trial Radar · NCT06449001

Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis

A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular Hemolysis

Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Aug 11, 2025

Primary completion

May 28, 2027

Study completion Mar 10, 2028

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Jun 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate efficacy of danicopan as add-on treatment to ravulizumab or eculizumab as assessed by hemoglobin (Hgb) change from Baseline at Week 12 in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH) and clinically significant extravascular hemolysis (CS-EVH).

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria
  • PNH
  • Extravascular Hemolysis

Interventions

  • DanicopanDrug

    Participants will receive danicopan on a weight-based dosing regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin (Hgb) Concentration at Week 12Time frame: Baseline, Week 12

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Saskatoon, Saskatchewan, Canada · Recruiting

  • Research Site

    Paris, France · Recruiting

  • Research Site

    Leeds, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.